Their view was that although some day to day fluctuation in functional abilities was characteristic of brain damage due to cerebrovascular disease, further sustained functional improvement of a significant degree was unlikely.

BBC: Straw's statement in full

Eli Lilly, however, is proceeding with its solanezumab compound, which slowed cognitive decline in patients with mild disease, but showed no statistically significant reduction in functional decline ( see this).

FORBES: Merck Makes A 'Speculative' Step Into Alzheimer's